Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
4.740
-0.180 (-3.66%)
Streaming Delayed Price
Updated: 12:38 PM EST, Jan 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
January 09, 2026
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From
Evolus
Via
Business Wire
Evolus Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Evolus
Via
Business Wire
Evolus to Participate in 2025 Stifel Healthcare Conference
October 28, 2025
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter Financial Results on November 5, 2025
October 22, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2025
From
Evolus
Via
Business Wire
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
September 08, 2025
From
Evolus
Via
Business Wire
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
August 25, 2025
From
Evolus
Via
Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
August 20, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 05, 2025
From
Evolus
Via
Business Wire
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
July 31, 2025
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter Financial Results on August 5, 2025
July 22, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2025
From
Evolus
Via
Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
July 09, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025
From
Evolus
Via
Business Wire
Evolysse™ Recognized in 2025 Shape Skin Awards
June 10, 2025
From
Evolus
Via
Business Wire
Evolus Announces Departure of its Chief Financial Officer
May 27, 2025
From
Evolus
Via
Business Wire
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
May 22, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From
Evolus
Via
Business Wire
Evolus Reports First Quarter 2025 Results
May 07, 2025
From
Evolus
Via
Business Wire
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
May 05, 2025
From
Evolus
Via
Business Wire
Evolus to Report First Quarter Financial Results on May 7, 2025
April 23, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2025
From
Evolus
Via
Business Wire
Evolus Announces Commercial Launch of Evolysse™
April 16, 2025
From
Evolus
Via
Business Wire
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
April 15, 2025
From
Evolus
Via
Business Wire
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
March 25, 2025
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2025
From
Evolus
Via
Business Wire
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
March 04, 2025
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
